Gallop Oncology is a clinical-stage  biopharma company leading development of drugs targeting galectin-9, a pivotal oncogenic and immunosuppressive regulator of cancer processes 

We are focused on transforming treatment paradigms for both hematologic and solid tumor indications. Our lead asset, LYT-200, has received Fast Track and Orphan Drug Designations for the treatment of acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC). With its dual mechanism of action—direct tumor suppression and immune modulation—LYT-200 represents a novel, differentiated approach in oncology therapeutics.

Biotechnology

Gallop Oncology

Org chart

Teams

Offices